Drs. Siefker-Radtke, Koshkin on the NORSE Study for Metastatic Urothelial Carcinoma

By Arlene O. Siefker-Radtke, MD, Vadim Koshkin, MD - Last Updated: June 15, 2023

Arlene O. Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, and Vadim Koshkin, MD, University of California, San Francisco, detail the phase 2 NORSE study design, results, and implications for treating patients with metastatic urothelial carcinoma and FGFR alterations.

View more ASCO 2023 videos.

Real-world Association of Tumor-Informed MRD With Clinical Outcomes for MIBC

Ajitha Kommalapati, MDASCO 2023 | August 15, 2023

Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.

Drs. Gupta, Koshkin on EV-103 Cohort K Results and Toxicities

Shilpa Gupta, MDASCO 2023 | August 4, 2023

Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.

Drs. Gupta, Koshkin on EV-103 Design and Long-term Cohort A Results for Patients With aUC

Shilpa Gupta, MDASCO 2023 | August 31, 2023

Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.

Biomarkers of Response to SG and EV in Advanced Urothelial Carcinoma: Analysis of the UNITE Study

Tanya JindalASCO 2023 | July 28, 2023

Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.

Dr. Thomas Hutson on Long-Term Durable Response After 4 Years Follow-Up in the CLEAR Study

Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023

Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.

Drs. Siefker-Radtke, Koshkin on the NORSE Study for Metastatic Urothelial Carcinoma

Related Posts